Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma
Anti-PD-L1 antibody monotherapy shows limited efficacy in a significant proportion of the patients. A common explanation for the inefficacy is a lack of anti-tumor effector cells in the tumor microenvironment (TME). Recombinant human interleukin-15 (hIL15), a potent immune stimulant, has been invest...
Main Authors: | Fei-Ting Hsu, Yu-Chang Liu, Chang-Liang Tsai, Po-Fu Yueh, Chih-Hsien Chang, Keng-Li Lan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/8/1789 |
Similar Items
-
Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
by: Yuyin Fu, et al.
Published: (2021-07-01) -
Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
by: Umang Swami, et al.
Published: (2020-10-01) -
PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab
by: Gabriele Madonna, et al.
Published: (2018-12-01) -
Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
by: Guillaume Herbreteau, et al.
Published: (2021-04-01) -
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
by: Jiyun Lee, et al.
Published: (2019-08-01)